Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04241276 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer

Study acronym: STARPAC2
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv4
  2. Primary completion date: Nov 30, 2024 to Jun 29, 2028
    • Study completion date: May 29, 2025 to Feb 28, 2029
    v3
  3. Primary completion date: Feb 22, 2024 to Nov 30, 2024v2 Show 5 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 1
    • Study completion date: May 29, 2024 to May 29, 2025
    • Secondary endpoints: details revised at 5 of 6 entries
    • Study title shortened, about 1 word
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, multi-centre, randomised, stratified, phase IIb clinical trial of ATRA administered in combination with gemcitabine and nab-paclitaxel in patients with laPDAC.
Trial Details
NCT Number NCT04241276
Lead Sponsor Queen Mary University of London
Collaborators: Medical Research Council, Celgene
Conditions
(from sponsor)		 Pancreatic Cancer
Related terms Pancreatic Neoplasms
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov